Flputnam Investment Management Co. Buys Shares of 10,080 Becton, Dickinson and Company $BDX

Flputnam Investment Management Co. acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 10,080 shares of the medical instruments supplier’s stock, valued at approximately $1,525,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company during the 4th quarter worth $26,000. Meeder Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Finally, Prosperity Bancshares Inc bought a new position in Becton, Dickinson and Company in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $182.39 on Tuesday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business has a 50 day moving average price of $158.48 and a 200-day moving average price of $161.26. The company has a market cap of $50.26 billion, a PE ratio of 54.94, a price-to-earnings-growth ratio of 12.93 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the firm earned $3.68 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 11,779 shares of company stock worth $1,974,669 over the last quarter. 0.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BDX. UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. Royal Bank Of Canada upped their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.